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ABSTRACT 
Different coagulation and fibrinolysis parameters were investi- 
gated in 149 patients with metastatic and non-metastatic tumours 
and results were compared with those obtained in a healthy popu- 
lation. Results showed a significant increase of thrombin-anti- 
thrombin complexes, fibrinopeptide A (FPA) and fibrin monomers 
in the group of patients (p< 0.001). There was also a signifi- 
cant prolongation of euglobulin lysis time (p< 0.005) and an 
increase of plasminogen activator inhibitor activity (p< O.OOOl), 
fibrinogen degradation products (p< O.OOl), and D-dimer (p< 0.05) 
in the group of patients as compared to controls: FPA levels 
were also increased in patients with metastases (p< 0.005). This 
study demonstrates clotting activation, at the level of fibrino- 
gen to fibrin conversion, and impairment of fibrinolysis in pa- 
tients with malignancy. 
INTRODUCTION 
The association of deep venous thrombosis with malignancy (Trousseau 
syndrome) is poorly understood and but the underlying mechanisms respon- 
sible for alterations in the clotting system are far from being establi- 
shed (l-3). Tumours may release substances into the circulation that di- 
rectly or indirectly activate the coagulation mechanism and contribute to 
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fibrin deposits as demonstrated by histological and immunological methods 
(4,5). To which extent the fibrinolytic system is clearing these depo- 
sits, is uncertain. A relation between the fibrinolytic activity of tu- 
mour cells and their invasive potential has been suggested and there are 
many examples of increased plasminogen activator activity in malignant 
tissues as compared to their normal counterparts (6,7). Some authors have 
found an increase in plasminogen activators in the blood of patients with 
carcinomas (8,9) whereas others have shown reduced blood fibrinolytic ac- 
tivity (10-13). 
The aim of our work was to analyze the hypercoagulable state present 
in malignancy by studying the mechanism of thrombin formation, fibrinogen 
to fibrin conversion and the possible role of the main components of the 
fibrinolytic system. 
PATIENTS AND METHODS 
The study was carried out in 149 patients with malignancy: 93 males 
and 56 females with a mean age of 57+13 years (range 17-81 years) of 
which 65 patients (44,8%) presented with local disease and 84 (55,2%) had 
metastases. Tumour localization was as follows: 61 gastro-intestinal 
(40.9%), 17 pulmonary (12%), 24 urological (16.1%), 16 gynaecological 
(10.7%) and 30 others (20.3%). No anti-inflammatory drugs were given 
during the week preceding the study. Forty-four age-sex matched healthy 
subjects served as control group. 
Blood from the antecubital vein was collected into 0.1 vol trisodium 
citrate (final concentration 0.011 M). Platelet-poor plasma was obtained 
by centrifugation for 15 min at 2.500 g and go C. Plasma samples for the 
fibrin plate assay and euglobulin lysis time were tested immediately 
whereas other samples were stored at -7OOC until use. For the determina- 
tion of fibrinopeptide A samples were collected on anticoagulant contai- 
ning sodium citrate, heparin and aprotinin. 
The assay of the thrombin-antithrombin (TAT) complex was performed by 
using an enzyme-immunoassay (Enzygnost TAT, Behring Institute, W. Germa- 
ny), of fibrinopeptide A (FPA) with an enzyme-immunoassay (ELISA FPA, 
Boehringer Mannheim, W. Germany) and of soluble fibrin in plasma was de- 
termined by a quantitative spectrophotometric assay according to Wiman 
and Ranby (14). Euglobulin lysis time (ELT) was performed according to 
von Kaulla et al (15). Fibrinolytic activity of the euglobul in fraction 
(EFA) was assessed on fibrin plates (16). Tissue-type plasminogen activa- 
tor (t-PA) activity was determined by a spectrophotometric assay (17) 
and t-PA antigen (t-PA Ag) using a t-PA ELISA kit (Biopool AB, Umea, 
Sweden ) . Plasminogen activator inhibitor (PAI) activity was measured as 
previously described (18). For the plasminogen and 0(2-antiplasmin 
(&2-AP) assay the chromogenic substrate (Kabi Diagnostica, Sweden ) was 
used. Fibrinogen degradation products (FDP) and fibrin degradation pro- 
ducts (D-dimer) were both measured according to a microelisa system using 
specific monoclonal antibodies FDP-Y18 (Fibrinostika FGDP) and FDP-DD13 
(Fibrinostika FBDP) respectively (Organon Teknika, the Netherlands). 
The data were statistically analyzed on the basis of mean values and 
standard deviations (SD). Student’s_t-test was used for comparison of 
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means between patients and controls and between patients with local 
disease and those with metastases. Analysis of variance was used for com- 
parison of results according to tumour localization. 
RESULTS ___. 
One hundred and forty nine patients with different malignancies were 
studied. There was a significant increase (p< 0.001) of TAT complexes 
(Fig 1) in patients (22.3k27.4 ug/l) as compared to controls (3.622.6 
ug/ml) . Fig 1 also shows a significant increase (PC 0.001) of f ibr ino- 
pept ide A and fibrin monomers in patients (13.7+14,3 ng/ml and 45.4+55.7 
nmol/l respectively) as compared to controls (4.424.2 ng/ml and t3.1+13.1 - 
nmol/l respectively). 
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Fig. 1. Mean (SD) concentrations of TAT complexes, FPA and fibrin mono- 
mers in patients (P) and controls (C). (*p< 0.001 with respect to control 
group). 
Figures 2 and 3 show the distribution of the fibrinolytrc parameters 
analyzed. A significant prolongation of ELT (p< 0.005) was found in pa- 
tients (286.2t111.6 min) as compared to controls (231.8558.7 min). There 
was a significant increase in PA1 activity (p< 0.0001) in paCients 
(2.1+1.5 U/ml) when compared to controls (0.9+0.9 U/ml). FDP concentra- 
tions were significantly higher (p< 0.001) in patients (l.lt2.3 ug/ml) 
than in controls (0.06+0.07 ug/ml). There was a slightly significant 
increase in D-dimer concentrations in patients (1.222.5 W/ml) as compa- 
red to controls (O.l+O,l ug/ml) (p< 0.05). EFA, t-PA activity and anti- 
gen, plasminogen, and 0(2-AP did not differ significantly between pa- 
tients and controls. 
No correlation was found between overall fibrinolytic activity and 
t-PA activity, nor between t-PA and PAI. 
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Fig. 2. ELT, EFA, t-PA activity, t-PA Ag and PAI in patients (P) and 
controls (C). Mean + SD is reported. (*p< 0.005 and ** p< 0.0001 with 
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Fig. 3. Mean (SD 
in patients (P 
to control group 
concentrations of plasminogen,0(2_AP, FPD and D-dimer 
and controls (C). (*p< 0.001 and **p< 0.05 with respect 
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Sixty-five patients presented with metastases and 84 with local 
disease. The values of the coagulation and fibrinolysis parameters analy- 
zed between patients with and without metastases is shown in Table I. 
Only the levels of FPA were significantly higher (p< 0.005) in patients 
with metastases as compared to those with local disease. 
TABLE 1 
Parameters analyzed in patient groups with and without 
metastases. Mean + SD is reported. 
PARAMETER Local disease Metastases 
(n= 84) (n= 65) 
TAT complex (ug/l) 19.7 + 23.7 
FPA (ng/ml) 10.8 + 11.3 
Fibrin monomers (nml/l) 44.3 + 57.8 
ELT (min) 278.9 + 91.3 
EFA (U/ml) 1.5 + 1.9 
t-PA activity (mIU/ml) 52.2 + 8.1 
t-PA Ag (ng/ml) 7.7 ; 6.9 
PA1 (U/ml) 1.9 + 1.2 
Plasminogen (8) 121.6 + 31.1 
0(2-AP (%) 96.7 + 27.2 
FDP (ug/ml) 1.1 + 2.2 
D-dimer (ug/ml) 0.9 ; 2.6 _ 
26.1 + 31.8 
17.5 + 16.9* 
47.1 2 52.9 
295.5 + 132.9 
1.3 ; 2.3 
49.9 ; 6.7 
7.1 ; 6.1 
2.2 ; 1.9 
120.6'+ 35.7 
92.1 : 22.2 
1.3 + 2.6 
1.6 5 2.4 
*p< 0.005 with respect to local disease 
There was no difference in the coagulation and fibrinolysis 
parameters according to tumour localization (not shown). 
DISCUSSION 
Patients with malignancies show different alterations of the clotting 
and fibrinolytic systems. Although these abnormalities most often cause 
no symptoms, up to 10-15X of patients present clinically evident thrombo- 
sis, which is a common cause of death in hospitalized cancer patients (2, 
19, 20). 
This study clearly demonstrates that activation of the coagulation 
system is common in patients with malignant disease. There was a signifi- 
cant increase of TAT complexes, FPA and fibrin monomers in the group of 
patients, suggesting thrombin generation followed by an increase of fi- 
brinogen to fibrin conversion. 
Generation of thrombin represents a central event within the coagula- 
tion cascade. Thrombin acts on different physiological substrates and is 
inhibited by antithrombin III, thereby forming an inactive proteinase/in- 
hibitor complex (21, 22). Determination of the TAT complex may be impor- 
tant in the diagnosis of thrombosis. Patients with risk factors for 
thrombosis and disseminated intravascular coagulation are found to have 
increased levels of TAT (23, 24). An increase of TAT complexes in pa- 
tients with malignancy has also been shown (25). 
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Fibrinogen to fibrin conversion was also enhanced in these patients 
as indicated by the raised FPA and fibrin monomers levels, suggesting an 
action of thrombin on its natural substrate with release of FPA and fi- 
brin monomer formation. It is known that tumours can produce coagulation 
activators such as tissue factor or activators of factor X. Monocytes 
from cancer patients are more likely to produce tissue factor, the amount 
of which can be correlated with FPA levels (26,27). We have also found 
increased FPA levels in patients with metastases indicating its possible 
role as a marker of tumoral activity. Similar results have been previous- 
ly reported as related to tumour progression (28, 29). Not to be over- 
looked, however, is the possibility that FPA may be generated at an ex- 
travascular site related to an enzyme that is not inhibited by heparin 
since it has been found that heparin does not reduce FPA levels in cancer 
patients (2, 29). 
The present study also demonstrates an impairment of the fibrinolytic 
system in cancer, which agrees with a previous study (13). It seems 
reasonable to assume that the alteration of fibrinolysis may represent an 
additional risk factor to be taken into consideration in the pathogenesis 
of thrombotic phenomena. 
Only limited data are available on plasminogen concentrations, plas- 
minogen activators and PA1 activity in the blood of patients suffering 
from oncologic disorders (30). We have found a significant prolongation 
of ELT and an increase of PA1 activity. In contrast, t-PA concentrations 
were normal, as shown both by functional and immunologic methods. The ob- 
servat ion that overall fibrinolytic activity does not correlate with t-PA 
activity could be explained by the fact that the euglobulin fraction con- 
tains other plasminogen activators, distinct from t-PA, which may contri- 
bute to the total activity. The increased PAI concentrations found in the 
patients studied are similar to those reported by other authors (11-13). 
No correlation was found between t-PA and PA1 which is not surprising 
since their release from the vascular endothelial cells, is independently 
regulated (31, 32). Moreover, a low concentration of plasminogen activa- 
tor and increased PA1 has been found to be present in patients with ve- 
nous thrombosis (33). Increased levels of PAI in the patient group cannot 
be attributed to an acute-phase reaction as only a few of the patients 
showed a weak inflammatory protein pattern and no differences between PA1 
levels and tumoral activity were observed. It can to be concluded that 
the enhancement of PAI activity may contribute to the impairment of blood 
fibrinolysis and thus represents an additional risk factor to be taken 
into account for explaining the thrombotic tendency of malignant disease. 
In spite of the reduced fibrinolytic activity there was an increase 
of FDP and D-dimer suggesting that the fibrinolytic system remains acti- 
ve. However, this increase, although statistically significant, does not 
appear to be biologically very relevant. On the other hand, the increased 
FDP and D-dimer levels does not necessarily derive from changes in the 
plasma fibrinolytic activity, but may be due to other causes, such as, 
breakdown of extravascular fibrin deposits or activity of enzymes diffe- 
rent from plasmin which may be produced by tumor cells (34-36). 
No differences in any of the fibrinolytic parameters analyzed were 
found either between patients with local disease and those with metasta- 
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ses or related to tumour localization. This would suggest that the obser- 
ved changes are not totally specific of malignant disease. 
In conclusion, we have found significant abnormalities in coagulation 
and fibrinolysis in patients with cancer. Thrombin generation, fibrinogen 
to fibrin conversion and impairment of fibrinolysis suggest a hypercoagu- 
lable state which may contribute to the thrombotic complications in these 
patients. 
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